Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances
In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatmen...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Xu, Wenfu [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
12 |
|---|
| Übergeordnetes Werk: |
Enthalten in: An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center - Phillips, Eileen ELSEVIER, 2014, Amsterdam |
|---|---|
| Übergeordnetes Werk: |
volume:124 ; year:2018 ; pages:168-179 ; extent:12 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.csda.2018.03.005 |
|---|
| Katalog-ID: |
ELV042741807 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV042741807 | ||
| 003 | DE-627 | ||
| 005 | 20230626002213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.csda.2018.03.005 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000578.pica |
| 035 | |a (DE-627)ELV042741807 | ||
| 035 | |a (ELSEVIER)S0167-9473(18)30053-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 540 |q VZ |
| 084 | |a 35.18 |2 bkl | ||
| 100 | 1 | |a Xu, Wenfu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 12 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. | ||
| 520 | |a In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. | ||
| 650 | 7 | |a Adaptive design |2 Elsevier | |
| 650 | 7 | |a Doubly adaptive biased coin design |2 Elsevier | |
| 650 | 7 | |a Non-inferiority trials |2 Elsevier | |
| 650 | 7 | |a Heterogeneous variances |2 Elsevier | |
| 650 | 7 | |a Familywise error rate |2 Elsevier | |
| 700 | 1 | |a Gao, Jingya |4 oth | |
| 700 | 1 | |a Hu, Feifang |4 oth | |
| 700 | 1 | |a Cheung, Siu Hung |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Phillips, Eileen ELSEVIER |t An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center |d 2014 |g Amsterdam |w (DE-627)ELV022563539 |
| 773 | 1 | 8 | |g volume:124 |g year:2018 |g pages:168-179 |g extent:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.csda.2018.03.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_130 | ||
| 936 | b | k | |a 35.18 |j Kolloidchemie |j Grenzflächenchemie |q VZ |
| 951 | |a AR | ||
| 952 | |d 124 |j 2018 |h 168-179 |g 12 | ||
| author_variant |
w x wx |
|---|---|
| matchkey_str |
xuwenfugaojingyahufeifangcheungsiuhung:2018----:epnedpieramnalctofroifroiyrasih |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
35.18 |
| publishDate |
2018 |
| allfields |
10.1016/j.csda.2018.03.005 doi GBV00000000000578.pica (DE-627)ELV042741807 (ELSEVIER)S0167-9473(18)30053-7 DE-627 ger DE-627 rakwb eng 610 VZ 540 VZ 35.18 bkl Xu, Wenfu verfasserin aut Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances 2018transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. Adaptive design Elsevier Doubly adaptive biased coin design Elsevier Non-inferiority trials Elsevier Heterogeneous variances Elsevier Familywise error rate Elsevier Gao, Jingya oth Hu, Feifang oth Cheung, Siu Hung oth Enthalten in Elsevier Science Phillips, Eileen ELSEVIER An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center 2014 Amsterdam (DE-627)ELV022563539 volume:124 year:2018 pages:168-179 extent:12 https://doi.org/10.1016/j.csda.2018.03.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_130 35.18 Kolloidchemie Grenzflächenchemie VZ AR 124 2018 168-179 12 |
| spelling |
10.1016/j.csda.2018.03.005 doi GBV00000000000578.pica (DE-627)ELV042741807 (ELSEVIER)S0167-9473(18)30053-7 DE-627 ger DE-627 rakwb eng 610 VZ 540 VZ 35.18 bkl Xu, Wenfu verfasserin aut Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances 2018transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. Adaptive design Elsevier Doubly adaptive biased coin design Elsevier Non-inferiority trials Elsevier Heterogeneous variances Elsevier Familywise error rate Elsevier Gao, Jingya oth Hu, Feifang oth Cheung, Siu Hung oth Enthalten in Elsevier Science Phillips, Eileen ELSEVIER An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center 2014 Amsterdam (DE-627)ELV022563539 volume:124 year:2018 pages:168-179 extent:12 https://doi.org/10.1016/j.csda.2018.03.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_130 35.18 Kolloidchemie Grenzflächenchemie VZ AR 124 2018 168-179 12 |
| allfields_unstemmed |
10.1016/j.csda.2018.03.005 doi GBV00000000000578.pica (DE-627)ELV042741807 (ELSEVIER)S0167-9473(18)30053-7 DE-627 ger DE-627 rakwb eng 610 VZ 540 VZ 35.18 bkl Xu, Wenfu verfasserin aut Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances 2018transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. Adaptive design Elsevier Doubly adaptive biased coin design Elsevier Non-inferiority trials Elsevier Heterogeneous variances Elsevier Familywise error rate Elsevier Gao, Jingya oth Hu, Feifang oth Cheung, Siu Hung oth Enthalten in Elsevier Science Phillips, Eileen ELSEVIER An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center 2014 Amsterdam (DE-627)ELV022563539 volume:124 year:2018 pages:168-179 extent:12 https://doi.org/10.1016/j.csda.2018.03.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_130 35.18 Kolloidchemie Grenzflächenchemie VZ AR 124 2018 168-179 12 |
| allfieldsGer |
10.1016/j.csda.2018.03.005 doi GBV00000000000578.pica (DE-627)ELV042741807 (ELSEVIER)S0167-9473(18)30053-7 DE-627 ger DE-627 rakwb eng 610 VZ 540 VZ 35.18 bkl Xu, Wenfu verfasserin aut Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances 2018transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. Adaptive design Elsevier Doubly adaptive biased coin design Elsevier Non-inferiority trials Elsevier Heterogeneous variances Elsevier Familywise error rate Elsevier Gao, Jingya oth Hu, Feifang oth Cheung, Siu Hung oth Enthalten in Elsevier Science Phillips, Eileen ELSEVIER An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center 2014 Amsterdam (DE-627)ELV022563539 volume:124 year:2018 pages:168-179 extent:12 https://doi.org/10.1016/j.csda.2018.03.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_130 35.18 Kolloidchemie Grenzflächenchemie VZ AR 124 2018 168-179 12 |
| allfieldsSound |
10.1016/j.csda.2018.03.005 doi GBV00000000000578.pica (DE-627)ELV042741807 (ELSEVIER)S0167-9473(18)30053-7 DE-627 ger DE-627 rakwb eng 610 VZ 540 VZ 35.18 bkl Xu, Wenfu verfasserin aut Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances 2018transfer abstract 12 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. Adaptive design Elsevier Doubly adaptive biased coin design Elsevier Non-inferiority trials Elsevier Heterogeneous variances Elsevier Familywise error rate Elsevier Gao, Jingya oth Hu, Feifang oth Cheung, Siu Hung oth Enthalten in Elsevier Science Phillips, Eileen ELSEVIER An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center 2014 Amsterdam (DE-627)ELV022563539 volume:124 year:2018 pages:168-179 extent:12 https://doi.org/10.1016/j.csda.2018.03.005 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_130 35.18 Kolloidchemie Grenzflächenchemie VZ AR 124 2018 168-179 12 |
| language |
English |
| source |
Enthalten in An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center Amsterdam volume:124 year:2018 pages:168-179 extent:12 |
| sourceStr |
Enthalten in An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center Amsterdam volume:124 year:2018 pages:168-179 extent:12 |
| format_phy_str_mv |
Article |
| bklname |
Kolloidchemie Grenzflächenchemie |
| institution |
findex.gbv.de |
| topic_facet |
Adaptive design Doubly adaptive biased coin design Non-inferiority trials Heterogeneous variances Familywise error rate |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center |
| authorswithroles_txt_mv |
Xu, Wenfu @@aut@@ Gao, Jingya @@oth@@ Hu, Feifang @@oth@@ Cheung, Siu Hung @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV022563539 |
| dewey-sort |
3610 |
| id |
ELV042741807 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042741807</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626002213.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.csda.2018.03.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000578.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042741807</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-9473(18)30053-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.18</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Xu, Wenfu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adaptive design</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Doubly adaptive biased coin design</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-inferiority trials</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Heterogeneous variances</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Familywise error rate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gao, Jingya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hu, Feifang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheung, Siu Hung</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Phillips, Eileen ELSEVIER</subfield><subfield code="t">An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV022563539</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:124</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:168-179</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.csda.2018.03.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_130</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.18</subfield><subfield code="j">Kolloidchemie</subfield><subfield code="j">Grenzflächenchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">124</subfield><subfield code="j">2018</subfield><subfield code="h">168-179</subfield><subfield code="g">12</subfield></datafield></record></collection>
|
| author |
Xu, Wenfu |
| spellingShingle |
Xu, Wenfu ddc 610 ddc 540 bkl 35.18 Elsevier Adaptive design Elsevier Doubly adaptive biased coin design Elsevier Non-inferiority trials Elsevier Heterogeneous variances Elsevier Familywise error rate Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances |
| authorStr |
Xu, Wenfu |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV022563539 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 540 VZ 35.18 bkl Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances Adaptive design Elsevier Doubly adaptive biased coin design Elsevier Non-inferiority trials Elsevier Heterogeneous variances Elsevier Familywise error rate Elsevier |
| topic |
ddc 610 ddc 540 bkl 35.18 Elsevier Adaptive design Elsevier Doubly adaptive biased coin design Elsevier Non-inferiority trials Elsevier Heterogeneous variances Elsevier Familywise error rate |
| topic_unstemmed |
ddc 610 ddc 540 bkl 35.18 Elsevier Adaptive design Elsevier Doubly adaptive biased coin design Elsevier Non-inferiority trials Elsevier Heterogeneous variances Elsevier Familywise error rate |
| topic_browse |
ddc 610 ddc 540 bkl 35.18 Elsevier Adaptive design Elsevier Doubly adaptive biased coin design Elsevier Non-inferiority trials Elsevier Heterogeneous variances Elsevier Familywise error rate |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
j g jg f h fh s h c sh shc |
| hierarchy_parent_title |
An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center |
| hierarchy_parent_id |
ELV022563539 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry |
| hierarchy_top_title |
An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV022563539 |
| title |
Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances |
| ctrlnum |
(DE-627)ELV042741807 (ELSEVIER)S0167-9473(18)30053-7 |
| title_full |
Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances |
| author_sort |
Xu, Wenfu |
| journal |
An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center |
| journalStr |
An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
168 |
| author_browse |
Xu, Wenfu |
| container_volume |
124 |
| physical |
12 |
| class |
610 VZ 540 VZ 35.18 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Xu, Wenfu |
| doi_str_mv |
10.1016/j.csda.2018.03.005 |
| dewey-full |
610 540 |
| title_sort |
response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances |
| title_auth |
Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances |
| abstract |
In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. |
| abstractGer |
In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. |
| abstract_unstemmed |
In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_130 |
| title_short |
Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances |
| url |
https://doi.org/10.1016/j.csda.2018.03.005 |
| remote_bool |
true |
| author2 |
Gao, Jingya Hu, Feifang Cheung, Siu Hung |
| author2Str |
Gao, Jingya Hu, Feifang Cheung, Siu Hung |
| ppnlink |
ELV022563539 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.csda.2018.03.005 |
| up_date |
2024-07-06T16:58:44.080Z |
| _version_ |
1803849694271504384 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042741807</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626002213.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.csda.2018.03.005</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000578.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042741807</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-9473(18)30053-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.18</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Xu, Wenfu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Response-adaptive treatment allocation for non-inferiority trials with heterogeneous variances</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">12</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In clinical studies, patients usually accrue sequentially. The response-adaptive design has been shown to be a valuable treatment allocation apparatus that skews the treatment allocation probabilities to achieve certain objectives such as reducing the number of patients who receive inferior treatments. The doubly adaptive biased coin design was successfully derived for the three-arm non-inferiority (NI) trial. For an NI study, an experimental treatment can be considered a possible substitute for the standard treatment if the loss of clinically tolerable efficacy is compensated by benefits such as the alleviation of side effects. Previous applications of the doubly adaptive biased coin design in NI trials were developed only for homogeneous treatment variances. However, it is worth to examine the more complicated, but nevertheless popular, scenarios in which the treatment variances are heterogeneous. The proposed treatment allocation scheme is superior when the treatment variances differ and remains very competitive when they are homogeneous. A clinical example is given for demonstrative purposes.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adaptive design</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Doubly adaptive biased coin design</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-inferiority trials</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Heterogeneous variances</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Familywise error rate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gao, Jingya</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hu, Feifang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cheung, Siu Hung</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Phillips, Eileen ELSEVIER</subfield><subfield code="t">An Orthopaedic Pre-operative Skin Decolonization Protocol Process Improvement Project at an Academic Medical Center</subfield><subfield code="d">2014</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV022563539</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:124</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:168-179</subfield><subfield code="g">extent:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.csda.2018.03.005</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_130</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.18</subfield><subfield code="j">Kolloidchemie</subfield><subfield code="j">Grenzflächenchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">124</subfield><subfield code="j">2018</subfield><subfield code="h">168-179</subfield><subfield code="g">12</subfield></datafield></record></collection>
|
| score |
7.4004955 |